Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | PGR | P06401 | 5/20 | 0.73 |
| ▸ | AR | P10275 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SHBG | P04278 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | SNCA | P37840 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045019 | 1.00 | CYP3A4 (0.73) | CYP3A4PGRARALDH1A1CYP2C19 | |
| SCHEMBL2045021 | 1.00 | CYP3A4 (0.73) | CYP3A4PGRARALDH1A1CYP2C19 | |
| SCHEMBL23563828 | 0.86 | PGR (0.71) | CYP3A4PGRARALDH1A1CYP2C19 | |
| SCHEMBL18767708 | 0.86 | PGR (0.71) | CYP3A4PGRARALDH1A1CYP2C19 | |
| SCHEMBL11429970 | 0.86 | CYP19A1 (0.57) | CYP3A4PGRARALDH1A1CYP2C19 | |
| Dydrogesterone SCHEMBL11512798 | 0.85 | CYP3A4 (1.00) | CYP3A4PGRARALDH1A1CYP2C19 | |
| Dydrogesterone SCHEMBL18814051 | 0.85 | CYP3A4 (1.00) | CYP3A4PGRARALDH1A1CYP2C19 | |
| Dydrogesterone SCHEMBL23383832 | 0.85 | CYP3A4 (1.00) | CYP3A4PGRARALDH1A1CYP2C19 | |
| Dydrogesterone SCHEMBL606817 | 0.85 | CYP3A4 (1.00) | CYP3A4PGRARALDH1A1CYP2C19 | |
| Dydrogesterone SCHEMBL606816 | 0.85 | CYP3A4 (1.00) | CYP3A4PGRARALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108531-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event | ACERUS BIOPHARMA INC (CA) | 2026-04-23 | — | — | US | disclosed |
| US-12474324-B2 | Method of making an aromagraph comprising ectopic olfactory receptors | SUNTORY HOLDINGS LIMITED (JP) | 2025-11-18 | — | — | US | disclosed |
| US-20250064831-A1 | CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS | ACERUS BIOPHARMA INC (CA) | 2025-02-27 | — | — | US | disclosed |
| CN-112805006-B | PRMT5 inhibitors | 默沙东有限责任公司 | 2024-09-24 | — | — | CN | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11744838-B2 | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | ACERUS BIOPHARMA INC. (CA) | 2023-09-05 | — | — | US | disclosed |
| US-11707467-B2 | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use | LIPOCINE INC. | 2023-07-25 | — | — | US | disclosed |
| US-20220370475-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis Event | FIRST GENERATION CAPITAL INC. (CA) | 2022-11-24 | — | — | US | disclosed |
| US-11433083-B2 | High-strength testosterone undecanoate compositions | LIPOCINE INC. | 2022-09-06 | — | — | US | disclosed |
| US-6413951-B2 | ENZYME INHIBITOR | AVENTIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1209227-A2 | Cytochrome P450 hydroxylase, an important enzyme in brassinosteroid biosynthesis of plants | Korea Kumho Petrochemical Co. Ltd. (KR) | 2002-05-29 | — | — | EP | disclosed |
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2002000681-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | AVENTIS PHARMA S.A. (FR) | 2002-01-03 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-6228595-B1 | OLIGONUCLEOTIDES OF SPECFIC NUCLEOTIDE SEQUENCES; FOR SENSITIVE, QUANTITATIVE, AUTOMATABLE ASSAY | G.D. SEARLE & CO. | 2001-05-08 | — | — | US | disclosed |
| US-6127117-A | OLIGONUCLEOTIDES WHICH DETECT EXPRESSION OF NUCLEOTIDE SEQUENCES THAT CODE ISOENZYMES OF ENZYMATIC PROTEINS; FOR DETECTING CHEMICAL INDUCTION OF ENZYME EXPRESSION; FOR EVALUTING THE EFFECTS OF XENOBIOTICS ON GENE EXPRESSION | G. D. SEARLE & CO. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-1997043448-A2 | ANALYSIS OF EXPRESSION OF RAT CYTOCHROME P450 ISOENZYMES AND PHASE II CONJUGATING ENZYMES | G.D. SEARLE & CO. (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4076708-A | Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby | SCHERING CORPORATION (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370475-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis Event | SHBG, NR5A1, CYP17A1 | CYP3A4 983/4885PGR 497/4885AR 5/4885 |
| US-11744838-B2 | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | SHBG, NR5A1, CYP17A1 | CYP3A4 983/4885PGR 497/4885AR 5/4885 |
| US-20260108531-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event | SHBG, AR, CYP17A1 | CYP3A4 242/4885PGR 321/4885AR 2/4885 |
| US-20250064831-A1 | CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS | SHBG, NR5A1, SRD5A1 | CYP3A4 386/4885PGR 250/4885AR 13/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | CYP3A4 3382/4885PGR 28/4885AR 9/4885 |
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | CYP17A1, HSD17B11, HSD3B1 | CYP3A4 167/4885PGR 122/4885AR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.